Michael Plotz
Overview
Explore the profile of Michael Plotz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
202
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hossini A, Quast A, Plotz M, Grauel K, Exner T, Kuchler J, et al.
PLoS One
. 2016 May;
11(5):e0154770.
PMID: 27138223
Apoptosis is a highly conserved biochemical mechanism which is tightly controlled in cells. It contributes to maintenance of tissue homeostasis and normally eliminates highly proliferative cells with malignant properties. Induced...
2.
Quast S, Steinhorst K, Plotz M, Eberle J
J Invest Dermatol
. 2015 Jul;
135(11):2794-2804.
PMID: 26134947
The death ligand TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) represents a promising strategy for melanoma due to significant expression of TRAIL receptor 1 in melanoma metastases and high TRAIL sensitivity...
3.
Plotz M, Eberle J
Exp Dermatol
. 2014 Mar;
23(6):375-8.
PMID: 24673301
Despite recent developments for new targeted therapies in melanoma, as BRAF inhibitors and immune-stimulating antibodies, tumor relapse frequently follows within less than a year. Therapy resistance is explained by defects...
4.
Quast S, Berger A, Plotz M, Eberle J
Eur J Cell Biol
. 2013 Dec;
93(1-2):42-8.
PMID: 24361324
The death ligand TRAIL (TNF-related apoptosis-inducing ligand) represents a promising therapeutic strategy for metastatic melanoma, however prevalent and inducible resistance limits its applicability and therapeutic use. Recent work has revealed...
5.
Berger A, Quast S, Plotz M, Kuhn N, Trefzer U, Eberle J
J Invest Dermatol
. 2013 Aug;
134(2):430-440.
PMID: 23955071
Mutated BRAF represents a critical oncogene in melanoma, and selective inhibitors have been approved for melanoma therapy. However, the molecular consequences of RAF inhibition in melanoma cells remained largely elusive....
6.
Erben F, Kleeblatt D, Sonneck M, Hein M, Feist H, Fahrenwaldt T, et al.
Org Biomol Chem
. 2013 May;
11(24):3963-78.
PMID: 23673975
Selenoindirubins and selenoindirubin-N-glycosides were prepared by the reaction of isatins and isatin-N-glycosides with 3-acetoxy-benzo[b]selenophene, respectively. While selenoindirubin-N-glycosides have not been reported before, three non-glycosylated selenoindirubins were previously reported, but without...
7.
Plotz M, Gillissen B, Quast S, Berger A, Daniel P, Eberle J
Cancer Lett
. 2013 Feb;
335(1):100-8.
PMID: 23402819
Melanoma cells are characterized by apoptosis deficiency coinciding with reduced expression of the proapoptotic Bcl-2 protein Bim. An adenoviral vector was constructed with the BimL cDNA controlled by an inducible...
8.
Al-Yacoub N, Fecker L, Mobs M, Plotz M, Braun F, Sterry W, et al.
J Invest Dermatol
. 2012 May;
132(9):2263-74.
PMID: 22551975
Suberoylanilide hydroxamic acid (SAHA) has been approved for the treatment of cutaneous T-cell lymphoma (CTCL), but its mode of action remained largely elusive. As shown here in four CTCL cell...
9.
Plotz M, Hossini A, Gillissen B, Daniel P, Stockfleth E, Eberle J
PLoS One
. 2012 Apr;
7(4):e34549.
PMID: 22506026
The BH3 domain of Bcl-2 proteins was regarded as indispensable for apoptosis induction and for mutual regulation of family members. We recently described Bcl-x(AK), a proapoptotic splice product of the...
10.
Braun F, Al-Yacoub N, Plotz M, Mobs M, Sterry W, Eberle J
J Invest Dermatol
. 2011 Oct;
132(2):429-39.
PMID: 22011910
Cutaneous T-cell lymphomas (CTCL) form a heterogeneous group of non-Hodgkin's lymphomas of the skin. In previous studies, we had characterized CTCL cells as resistant to the death ligand tumor necrosis...